Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From UnitedHealth Group
According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval.
As they revise and interpret merger guidelines, the Federal Trade Commission and Department of Justice should pay particular attention to the anticompetitive impact of consolidation in the pharmacy benefit manager market, the generic trade group suggests.
After motion to advance fails at 17 February meeting, proposed study design will be revamped, not scrapped. Despite the 2-2 deadlock on the vote, commissioners uniformly expressed an interest in proceeding with research on PBM industry, focusing on the leading players.
The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.
- Other Names / Subsidiaries